JGJames N. George

James N. George

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James N. George has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Continuing Medical Education Program inTransfusion

    by Sumit Som, Cassandra C. Deford, Mandi L. Kaiser, Deirdra R. Terrell, Johanna A. Kremer Hovinga, Bernhard Lämmle, James N. George, Sara K. Vesely

    • 1 November 2007
      • Vol. 100  (11) , 429-33

    Endemic Esherichia coil O157:H7 infections and hemolytic-uremic syndrome in Oklahoma, 2002-2005.

    by Charity A Karpac, Anthony Lee, Binitha S Kunnel, Oluwatoyin F Bamgbola, Sara K Vesely, James N George

    Hemorrhagic enterocolitis caused by Escherichia coli O157:H7 and its complication of hemolytic-uremic syndrome (HUS) are well known from large outbreaks caused by contaminated meats and vegetables. However most cases may be endemic, not related to an outbreak. We identified cases of HUS in Oklahoma, 2002-2005, from the Inpatient Hospital Discharge Database of the Oklahoma State Department of Health (OSDH) and also the cases of HUS and E. coli O157:H7 reported to the OSDH. 110 cases of HUS were identified from the hospital discharge database; only 14 (12.7%) were reported to the OSDH; 122 cases of E. coli O157:H7 infections were reported to the OSDH. Of the 110 cases of HUS, only six (5.5%) patients in two separate clusters may have had a common source of infection. Although interpretation is limited by the few reports to OSDH, our data suggest that E. coli O157:H7 infections and HUS, presumably related to contaminated food, are endemic throughout Oklahoma.


    • 1 July 2007
      • Vol. 100  (7) , 273-8

    The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a community service.

    by Kristina K Johnson, Deanna Duvall, Ronald O Gilcher, James W Smith, Jean E Forsberg, Deirdra R Terrell, Sara K Vesely, James N George

    The Oklahoma Thrombotic ThrombocytopenicPurpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry has enrolled all 335 consecutive patients from central, western and southeastern Oklahoma who had their first episode of clinically diagnosed TTP or HUS from 1989 through 2005; follow-up is complete for 333 patients. Identifying all patients is possible since plasma exchange is the essential treatment for all adults and some children with these disorders and since the Oklahoma Blood Institute (OBI) is the sole provider of plasma exchange services for this region. Patients in the Oklahoma TTP-HUS Registry have come from 46 counties and have been treated in 16 hospitals; 227 physicians have provided the principal care for these patients. A support group formed in 1996 has met 3 times each year, averaging 17 former patients plus 16 additional family members and friends. Registry data are an important source of information for physicians and their patients, providing a complete community perspective of these uncommon disorders.


  • Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura–hemolytic uremic syndrome

    by Sara K. Vesely, Xiaoning Li, J.R. McMinn, Deirdra R. Terrell, James N. George

    BACKGROUND:  Recurrent thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (TTP‐HUS) during a subsequent pregnancy is an important concern because pregnancy may increase the risk for relapse.STUDY DESIGN AND METHODS:  Outcomes of all pregnancies after recovery from TTP‐HUS in the Oklahoma TTP‐HUS Registry, a cohort of 301 consecutive patients during the period of 1989 through 2003, were assessed and compared to the total published experience.RESULTS:  In the Oklahoma Registry, 3 of 7 (43%) women with idiopathic TTP‐HUS, 2 of 11 (18%) women who were pregnant/postpartum, and 0 of 1 (0%) woman with a bloody diarrhea prodrome at their initial presentation were diagnosed with TTP‐HUS during a subsequent pregnancy; all 5 women recovered. In published reports, 10 of 11 (91%) women with idiopathic TTP‐HUS and 11 of 18 (61%) women who were pregnant/postpartum at their initial presentation, and all 11 (100%) women with congenital TTP‐HUS were diagnosed with TTP‐HUS during a subsequent pregnancy. Rates of recurrence in the Oklahoma Registry may be less because of case report bias for exceptional patients. Recurrent TTP‐HUS was difficult to diagnose because other pregnancy‐related complications were frequent.CONCLUSIONS:  Although pregnancies in these women were often complicated, a future pregnancy may be a safe and appropriate decision for women who have recovered from TTP‐HUS.


  • Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care

    by James N. George, Gary E. Raskob, Sara K. Vesely, Dennis Moore, Roger M. Lyons, Everardo Cobos, Brenda L. Towell, Panpit Klug, Troy H. Guthrie

    We conducted a randomized clinical trial in adults with a new diagnosis of ITP and a platelet count P = 0.045 at 100 days after randomization, P = 0.840 at 1 year after randomization, using log‐rank analysis). Patients in the anti‐D group were treated with prednisone for fewer days (70 days) compared to the routine care group (112 days, P = 0.01). No major bleeding events occurred. In this study, initial treatment of patients with intermittent anti‐D initially deferred splenectomy. Whether our aggressive regimen of anti‐D could have prevented splenectomy if it had been adhered to in all patients remains uncertain. However, compliance with this anti‐D regimen was not feasible for many patients and/or their physicians. Am. J. Hematol. 74:161–169, 2003.


  • The association of pregnancy with thrombotic thrombocytopenic purpura–hemolytic uremic syndrome

    by James N. George

    Thrombotic thrombocytopenic purpura–hemolytic uremic syndrome occurs more commonly in women and among women is commonly associated with pregnancy. Case series of thrombotic thrombocytopenic purpura–hemolytic uremic syndrome from 1964 to 2002 were reviewed (1) to document the reports of occurrence of thrombotic thrombocytopenic purpura–hemolytic uremic syndrome during pregnancy and (2) to search for reports of women with congenital or familial thrombotic thrombocytopenic purpura–hemolytic uremic syndrome who were initially diagnosed during their first pregnancy. The time during pregnancy with greatest risk for development of thrombotic thrombocytopenic purpura–hemolytic uremic syndrome is near term and during the postpartum period. This is also the time of greatest risk for thrombotic events and for the occurrence of other pregnancy-related syndromes: preeclampsia, eclampsia, and hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome. These other syndromes may also be associated with thrombocytopenia, microangiopathic hemolytic anemia, neurologic symptoms, and renal insufficiency, making their distinction from thrombotic thrombocytopenic purpura–hemolytic uremic syndrome difficult or impossible. The occurrence of preeclampsia and related syndromes, the hypercoaguable state that occurs in late pregnancy and postpartum, and the progressively decreasing concentration of ADAMTS13 that occurs during late pregnancy may combine to increase the risk for occurrence of thrombotic thrombocytopenic purpura–hemolytic uremic syndrome.


    • 1 September 2003
      • Vol. 2  (5) , 381-7

    Idiopathic thrombocytopenic purpura: current issues for pathogenesis, diagnosis, and management in children and adults.

    by James N George

    Current issues for idiopathic thrombocytopenic purpura (ITP) in children and adults are reviewed. Appropriate initial management of ITP in children is controversial. Some physicians favor specific treatment, whereas other physicians advocate only supportive care until the expected spontaneous remission occurs. In adults, ITP is typically persistent. Treatment is appropriate only for severe and symptomatic thrombocytopenia because prevention of bleeding is the only goal. If patients do not respond to initial glucocorticoid treatment, splenectomy is the appropriate second modality, resulting in sustained remissions in more than 66% of patients. For patients who have severe and symptomatic thrombocytopenia after splenectomy, treatment options are unclear. Intensive immunosuppression may be effective, but stimulation of platelet production by thrombopoietin may also be effective. Because major bleeding in ITP is rare, physicians must be certain that the adverse effects of treatment are not worse than the risks of bleeding caused by ITP.